AzTrials
AzTrials

TelemedicineTelescope_2NCT05960994

Evaluation of the Clinical Impact of Different Telemedicine Practices in Intensive Care Units

A study testing Intervention period in people with Telemedicine and Critical Care, run by Hospital Israelita Albert Einstein at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study is to assess whether an intervention package via telemedicine consisting of daily multidisciplinary rounds with a specialist in intensive care medicine, an intervention package provided by a specialized multiprofessional team (nursing, physical therapy and clinical pharmacy) and a… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Telemedicine, Critical Care, Intensive Care Units
What is being tested?
Intervention period
Could I receive a placebo?
No, everyone receives an active treatment
How many people
22,000 participants
Where
1 siteBrazil
Study dates
8 Jan 2024to 1 May 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Intensive care units from public or philanthropic hospitals.
  • ICUs with a minimum of 7 and a maximum of 20 beds.
  • Intensive care units with physician and nurses available 24 hours a day and physiotherapist available at least ≥ 18 hours a day.
  • Adult patients (≥ 18 years old).

Who cannot join

  • Intensive care units with structured multidisciplinary round more than three times a week conducted by an intensive care physician (certified), documented in the medical record, with a fixed duration (>5 min / patient), using some supporting tool (checklist or standard form), goal oriented, based on established protocols, including all the patients admitted to the ICU.
  • Intensive care units already doing audit and feedback with specific planning.
  • Dedicated coronary care units/cardiac intensive care units or other specialized units (cardiac surgery, neurological, burned patients).
  • Step-down units or semi-intensive cardiac care unit.
  • Intensive care units without availability of substitute renal therapy.
  • ICU coordinator specialist in intensive care medicine and management training (MBA in Health Management or equivalent).
  • Admission for other reasons than medical (e.g., judicial cause, legal reasons, safety reasons).
  • Previously included in the TELESCOPE II trial (for the primary outcome analysis).

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Einstein Hospital Israelita

    São Paulo, São Paulo, 05651-901

Other trials in Brazil

About this study

Official title: Evaluation of the Clinical Impact of Different Telemedicine Practices in Intensive Care Units: a Stepped-wedge Cluster Randomized Clinical Trial

The objective of this study is to assess whether an intervention package via telemedicine consisting of daily multidisciplinary rounds with a specialist in intensive care medicine, an intervention package provided by a specialized multiprofessional team (nursing, physical therapy and clinical pharmacy) and a management intervention package, focused on quality and safety, reduces the length of stay in ICU patients in Brazil. Our hypothesis is that the intervention package via telemedicine has the potential to decrease the length of stay in ICU patients in Brazil.

The study provides for the implementation of three interventions in association via telemedicine.

Read more
  • Daily multidisciplinary rounds conducted by a physician specialized in intensive care medicine
  • Intervention package by specialized multidisciplinary team (nursing, physiotherapy and clinical pharmacy).
  • Management intervention package (quality and safety).

The main questions it aims to answer are:

  • Length of stay in ICU
  • ICU mortality.
  • In-hospital mortality.
  • Ventilator-free days during the first 28 days.
  • ICU readmission within 48 hours.
  • Early reintubation (<48h after elective extubation).
  • Ventilator-associated events.
  • Accidental extubation rate.
  • Patient Mobilization Density.
  • Adherence to maintaining the head-of-bed elevation.
  • Adequate prevention of venous thromboembolism.
  • Rate of patient-days under adequate sedation.
  • Rate of patients-days with oral or enteral nutrition.
  • Rate of patients with adequate glycemic control.
  • Rate of patients-days within normoxemia.
  • Rate of central venous catheter use.
  • Central venous catheter dwell time.
  • Rate of indwelling urinary catheter use.
  • Indwelling urinary catheter dwell time.
  • Standard resource use.
  • Standardized mortality rate.
Read the detailed description

BACKGROUND:

ICU beds represent a scarce and high cost resource. This scenario is aggravated by the scarcity and heterogeneous distribution of specialists in intensive care medicine in Brazil. Telemedicine is an innovative and promising technology, with the possibility of making the daily multidisciplinary round accessible with the presence of intensive care medicine specialists throughout the national territory. In a previous study (Telescope Trial I), it was demonstrated that daily multidisciplinary round conducted via telemedicine by a remotely located medical specialist is a safe and feasible practice. However, little is known about different modalities of telemedicine care in the ICU environment, more specifically, about the impact of interventions performed by a multidisciplinary team (non-medical) and management interventions (quality and safety).

SAMPLE SIZE CALCULATION:

A total sample size of 18,750 to 25,000 patients will be considered to detect a reduction in the length of stay in the ICU on a logarithmic scale of 0.1479 (equivalent to a 1.1-day reduction compared to the baseline), resulting from the intervention package with a significance level of 5% and a minimum power of 95%. This variation in total sample size is due to different estimates of patients per period in the 25 Brazilian ICUs in question. It is estimated that there will be a variation of 30 to 40 patients recruited per month per ICU.

PRIMARY OUTCOME:

The primary outcome of this trial at the patient level is ICU length of stay (LOS) defined as the time interval in hours between patients' ICU admission and the moment of ICU physical discharge times (i.e., transfer to another care facility or another hospital) or ICU death, as defined by the hospital's system date and time. Date and time will be entered by the health care worker responsible for data collection. ICU LOS will be derived in 24 hours periods with decimal place.

SECONDARY OUTCOMES:

The secondary outcomes of this study include assessing the impact of interventions implemented through telemedicine compared with a control period in the following outcomes:

  • ICU mortality.
  • In-hospital mortality.
  • Ventilator-free days during the first 28 days.
  • ICU readmission within 48 hours.
  • Early reintubation (<48h after elective extubation).
  • Ventilator-associated events.
  • Accidental extubation rate.

Process-of-care and quality indicators

  • Patient mobilization density in the ICU.
  • Adherence to maintaining the head-of-bed elevation (30°-45°).
  • Adequate prevention of venous thromboembolism.
  • Rate of patient-days under adequate sedation [defined by Richmond agitation and sedation scale (RASS) = -3 to +1].
  • Rate of patients-days with oral or enteral nutrition.
  • Rate of patients with adequate glycemic control (defined as blood glucose = 70 to 180mg/dL).
  • Rate of patients-days within normoxemia (defined as peripheral oxygen saturation = 92 to 96%).
  • Rate of central venous catheter use.
  • Central venous catheter dwell time.
  • Rate of indwelling urinary catheter use.
  • Indwelling urinary catheter dwell time.

Unit-level organizational outcomes

  • Classification of the unit according to the profiles defined by standard resource use (SRU) and standardized mortality rate (SMR). SRU reflects the observed-to-expected rate of resource utilization, estimated as ICU LOS for surviving patients and adjusted for the patient's severity of illness. SMR reflects the observed / expected rate, according to acute physiology score (SAPS 3) of hospital deaths. The profiles are a combination of SMR (above or below median) and SRU (above or below median): Each unit can be assigned to one of four groups: 'most efficient' (SMR and SRU <median); 'least efficient' (SMR, SRU >median); 'overachieving' (low SMR, high SRU), 'underachieving' (high SMR, low SRU).

STATISTICAL ANALYSIS:

All analyses will be described in detail in a statistical analysis plan, which will be finalized and submitted for publication before the database is closed and analyses begin. The primary statistical analyses will be conducted according to the intention-to-treat principle. Since ICUs will be randomized (not patients) and outcomes will be measured at the patient level, all analyses will be adjusted for clustering of data.

The primary outcome, length of ICU stay, will be analyzed at the individual level using a generalized linear mixed model, including as fixed effect the group, and considering distributions that can fit an expected right skewness (such as truncated Poisson, Gamma or inverse Gaussian distribution, etc.), choosing the best fit according to model parameters. The goal of the mixed model is to be able to fit random vectors, taking into account the correlation of the observations of individuals in the same cluster. Thus, the model will have as random effect an intercept for each unit. To consider an eventual lack of balance, we will adjust the analysis model for the factors used in the stratification and for the outcome value at the unit level in the pre-randomization period (i.e., mean length of stay in the ICU of each unit), as suggested by the literature. Additionally, we will adjust for factors that have a correlation with length of stay, aiming to decrease variability between units, thus impacting intra cluster correlation and increasing the power of the study. The adjustment factors will be defined after the pre-randomization period data collection, and reported in a statistical analysis plan, published before closing the study database, as specified above. These factors are about severity (SAPS 3) and clinical or surgical profile. In the event of a significant amount of missing data on the primary endpoint, the analysis will be re-evaluated after using multiple imputation with chained equations, assuming that the data will be missing at random. Data collected during the transition period will not be analyzed for primary, secondary or exploratory endpoints.

Sensitivity analyses and subgroups for the primary outcome:

We will define, a priori, the following subgroups for analysis of the primary outcome:

A - ICU length of stay stratified by clinical vs elective surgical and emergency surgical patients.

B - Length of stay in ICU stratified by three groups (lower, middle and upper thirds) of severity determined by SAPS 3 score.

C - ICU length of stay stratified by mechanically ventilated patients on admission (invasive mechanical ventilation).

Similarly, in all other analyses, generalized linear mixed models will be used. Analyses of the pre-specified secondary outcomes and subgroup analyses will not be adjusted for multiple comparisons, thus should be interpreted as exploratory.

Due to the importance of the SAPS 3 severity score, we will evaluate the calibration of the model with data from the pre-randomization period. If necessary, we will recalibrate the model for the study population.

The significance level for all endpoints will be 0.05. All analyses will be performed with R software (version 4.2.0, the version will be updated at the time of the analysis).

REGULATORY STATUS:

The study will be conducted in accordance with the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Humans Act.

APPROVAL FROM ETHICS AND REGULATORY AUTHORITIES:

The study will be performed according to the national and international guidelines. The Institutional Review Board of the Hospital Israelita Albert Einstein has approved this study (CAAE: 69575123.0.1001.0071). The participating centers will not initiate the study until they have obtained approval from their respective local Institutional Review Boards. The need for informed consent is determined by the Institutional Review Board of each participating center.

Being tested
Intervention period
Keywords
Telemedicine, Critical care, Intensive care units

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intervention periodOther

    During the intervention period, three interventions will be implemented through telemedicine.

    1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
    2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
    3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Study groups in NCT05960994
Study groupRoleWhat they receive
Sequence 1ExperimentalSequence 1 will consist of a 3-month control period, followed by a 3-month transition period, and finally, a 19-month intervention period. The total duration of sequence 1 will be 25 months.
Receives: Other: Intervention period
Sequence 2ExperimentalSequence 2 will consist of a 7-month control period, followed by a 3-month transition period, and finally, a 15-month intervention period. The total duration of sequence 2 will be 25 months.
Receives: Other: Intervention period
Sequence 3ExperimentalSequence 3 will consist of a 11-month control period, followed by a 3-month transition period, and finally, a 9-month intervention period. The total duration of sequence 3 will be 25 months.
Receives: Other: Intervention period
Sequence 4ExperimentalSequence 4 will consist of a 15-month control period, followed by a 3-month transition period, and finally, a 7-month intervention period. The total duration of sequence 4 will be 25 months.
Receives: Other: Intervention period
Sequence 5ExperimentalSequence 5 will consist of a 19-month control period, followed by a 3-month transition period, and finally, a 3-month intervention period. The total duration of sequence 5 will be 25 months.
Receives: Other: Intervention period

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intensive Care Unit Length of Stay

    Defined as the time interval in hours between patients' ICU admission and the moment of ICU physical discharge times (i.e., transfer to another care facility or another hospital) or ICU death, as defined by the hospital's system date and time. Date and time will be entered by the health care worker responsible for data collection. ICU LOS will be derived in 24 hours periods with decimal place.

    Measured: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days

Secondary outcomes (7)
  1. ICU mortality

    Any death during Intensive Care Unit stay

    Measured: From date of randomization until the date of ICU death, assessed up to 90 days

  2. In-hospital mortality

    Any death during the index hospital admission.

    Measured: From date of randomization until the date of hospital discharge, assessed up to 90 days

  3. Ventilator-free days during the first 28 days

    Number of days alive and free from mechanical ventilation for at least 24 consecutive hours. Patients who died before weaning were deemed to have zero ventilator-free days, and patients discharged from the hospital before 28 days were considered alive and free from mechanical ventilation at 28 days.

    Measured: 28 Days

  4. ICU readmission within 48 hours.

    Readmission less than 48 hours after discharge

    Measured: From date of randomization until the date of hospital discharge or death, whichever comes first, assessed up to 90 days

  5. Early reintubation (<48h after elective extubation).

    Less than 48 hours after extubation

    Measured: From date of randomization until the date of hospital discharge or death, whichever comes first, assessed up to 90 days

  6. Ventilator-associated events

    Defined as either an increase in the daily minimum positive end-expiratory pressure (PEEP) of ≥3 cmH2O sustained for at least two consecutive calendar days following a period of at least two days of stable or decreasing PEEP, or an increase in the fraction of inspired oxygen (FiO2) by ≥20 percentage points sustained for at least two consecutive days after a minimum of two days of stable or decreasing FiO2 levels.

    Measured: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days

  7. Accidental extubation rate.

    Defined as the proportion of patients undergoing invasive mechanical ventilation who experience unplanned removal of the endotracheal tube.

    Measured: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jul 2023
  2. Study start8 Jan 2024
  3. Primary completion31 Jan 2026
  4. Study completion1 May 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Sequential
Model description
The TELESCOPE II study is an open-label, national, multicenter, stepped-wedge cluster randomized controlled trial. The randomization unit will be the ICU, since the intervention will be applied to the entire multiprofessional team. Therefore, 25 ICUs participating in the study will be allocated and randomized to one of the five sequences. In each sequence, the initial period will serve as the control period without any intervention. Subsequently, as the intervention is stepwise implemented, new control periods will be introduced based on the assigned sequence. Due to the multifaceted nature of the intervention, a delay in onset of effect is expected; thus, the study design contemplates a transition period, which will occur in all sequences, when the intervention will be occurring, but these data will not be used in the main analysis. All groups will receive all interventions, but at different times
Masking
None (open label)
Enrolment
22,000 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05960994
Sponsor's protocol ID
5535-23
Acronym
Telescope_2
Status last verified
Feb 2026
First submitted
30 Jun 2023
Last updated
18 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data sharing open to researchers not members of the study after two years of the publication of the main study.

Questions about this trial

What is this clinical trial studying?

A study testing Intervention period in people with Telemedicine and Critical Care, run by Hospital Israelita Albert Einstein at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intensive Care Unit Length of Stay (time frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in